Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate
Melioidosis is a severe infectious disease caused by Burkholderia pseudomallei. It is refractory to antibiotic treatment and there is currently no licensed vaccine. In this report we detail the construction and protective efficacy of a polysaccharide-protein conjugate composed of B. pseudomallei lip...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2014/392170 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849405470409752576 |
|---|---|
| author | Andrew E. Scott Sarah A. Ngugi Thomas R. Laws David Corser Claire L. Lonsdale Riccardo V. D’Elia Richard W. Titball E. Diane Williamson Timothy P. Atkins Joann L. Prior |
| author_facet | Andrew E. Scott Sarah A. Ngugi Thomas R. Laws David Corser Claire L. Lonsdale Riccardo V. D’Elia Richard W. Titball E. Diane Williamson Timothy P. Atkins Joann L. Prior |
| author_sort | Andrew E. Scott |
| collection | DOAJ |
| description | Melioidosis is a severe infectious disease caused by Burkholderia pseudomallei. It is refractory to antibiotic treatment and there is currently no licensed vaccine. In this report we detail the construction and protective efficacy of a polysaccharide-protein conjugate composed of B. pseudomallei lipopolysaccharide and the Hc fragment of tetanus toxin. Immunisation of mice with the lipopolysaccharide-conjugate led to significantly reduced bacterial burdens in the spleen 48 hours after challenge and afforded significant protection against a lethal challenge with B. pseudomallei. The conjugate generated significantly higher levels of antigen-specific IgG1 and IgG2a than in lipopolysaccharide-immunised mice. Immunisation with the conjugate also demonstrated a bias towards Th1 type responses, evidenced by high levels of IgG2a. In contrast, immunisation with unconjugated lipopolysaccharide evoked almost no IgG2a demonstrating a bias towards Th2 type responses. This study demonstrates the effectiveness of this approach in the development of an efficacious and protective vaccine against melioidosis. |
| format | Article |
| id | doaj-art-4b148131007d4b5cb25b8f4c6c672a8e |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-4b148131007d4b5cb25b8f4c6c672a8e2025-08-20T03:36:39ZengWileyJournal of Immunology Research2314-88612314-71562014-01-01201410.1155/2014/392170392170Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein ConjugateAndrew E. Scott0Sarah A. Ngugi1Thomas R. Laws2David Corser3Claire L. Lonsdale4Riccardo V. D’Elia5Richard W. Titball6E. Diane Williamson7Timothy P. Atkins8Joann L. Prior9Defence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKFleet Bioprocessing Ltd., Pale Lane Farm, Hartley Wintney RG27 8DH, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKCollege of Life and Environmental Sciences, University of Exeter, Exeter EX4 4QD, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKDefence Science and Technology Laboratory, Porton Down, Salisbury SP4 0JQ, UKMelioidosis is a severe infectious disease caused by Burkholderia pseudomallei. It is refractory to antibiotic treatment and there is currently no licensed vaccine. In this report we detail the construction and protective efficacy of a polysaccharide-protein conjugate composed of B. pseudomallei lipopolysaccharide and the Hc fragment of tetanus toxin. Immunisation of mice with the lipopolysaccharide-conjugate led to significantly reduced bacterial burdens in the spleen 48 hours after challenge and afforded significant protection against a lethal challenge with B. pseudomallei. The conjugate generated significantly higher levels of antigen-specific IgG1 and IgG2a than in lipopolysaccharide-immunised mice. Immunisation with the conjugate also demonstrated a bias towards Th1 type responses, evidenced by high levels of IgG2a. In contrast, immunisation with unconjugated lipopolysaccharide evoked almost no IgG2a demonstrating a bias towards Th2 type responses. This study demonstrates the effectiveness of this approach in the development of an efficacious and protective vaccine against melioidosis.http://dx.doi.org/10.1155/2014/392170 |
| spellingShingle | Andrew E. Scott Sarah A. Ngugi Thomas R. Laws David Corser Claire L. Lonsdale Riccardo V. D’Elia Richard W. Titball E. Diane Williamson Timothy P. Atkins Joann L. Prior Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate Journal of Immunology Research |
| title | Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate |
| title_full | Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate |
| title_fullStr | Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate |
| title_full_unstemmed | Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate |
| title_short | Protection against Experimental Melioidosis following Immunisation with a Lipopolysaccharide-Protein Conjugate |
| title_sort | protection against experimental melioidosis following immunisation with a lipopolysaccharide protein conjugate |
| url | http://dx.doi.org/10.1155/2014/392170 |
| work_keys_str_mv | AT andrewescott protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT sarahangugi protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT thomasrlaws protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT davidcorser protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT clairellonsdale protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT riccardovdelia protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT richardwtitball protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT edianewilliamson protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT timothypatkins protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate AT joannlprior protectionagainstexperimentalmelioidosisfollowingimmunisationwithalipopolysaccharideproteinconjugate |